In Vitro Models & Assay Development
Bioneer´s research strategy addresses novel solutions for drug discovery and development that fulfil future needs of companies, research institutes and Health Care.
To be successful in developing a drug candidate mode of action patterns needs to be resolved, therapeutic modalities needs to be tailored to provide optimal treatment and disease progression as well as therapeutic outcomeshave to be monitored.
We strive to develop “best-in-class” solutions and are currently running two ambitious R&D programs within:
- In Vitro Models & Assay Development
- Drug Candidate Development & Formulation.
CNS Modelling & Assays
In Vitro modelling in the CNS field is moving fast with technologies like CRISPR engineering, 3D models and continuously optimized neuronal differentiation protocols. For more than a decade, Bioneer has been working extensively with cell models in the CNS field.
Our R&D program is focusing on the development of neuronal models and image-based screening assays (Image Xpress platform), e.g. aggregation models mimicking pathological hallmarks of Alzheimer’s disease and Parkinson’s Disease as well as advanced co-culture models combining e.g. neurons and astrocytes and human blood-brain-barrier (BBB) models.
Our Image Xpress screening platform makes it possible to develop highly advanced multiparameter screening assays coupled to our CNS cell models.
During the program we will exploit the use of artificial intelligence to develop prediction tools based on various biological data generated from the CNS cell models. We will investigate the possibility of modelling the partitioning of drug molecules between the blood and the CNS in vitro, to be able to make predictions on drug translocation across the BBB.
Our CNS modelling program will enable us to continue and expand our role as integrated R&D partner to CNS focused companies worldwide.
Our R&D program is focusing on the development of neuronal models and image-based screening assays (Image Xpress platform), e.g. aggregation models mimicking pathological hallmarks of Alzheimer’s disease and Parkinson’s Disease as well as advanced co-culture models combining e.g. neurons and astrocytes and human blood-brain-barrier (BBB) models.
Our Image Xpress screening platform makes it possible to develop highly advanced multiparameter screening assays coupled to our CNS cell models.
During the program we will exploit the use of artificial intelligence to develop prediction tools based on various biological data generated from the CNS cell models. We will investigate the possibility of modelling the partitioning of drug molecules between the blood and the CNS in vitro, to be able to make predictions on drug translocation across the BBB.
Our CNS modelling program will enable us to continue and expand our role as integrated R&D partner to CNS focused companies worldwide.
Cancer Modelling & Assays
Bioneer has a long track record in biomarker research within the cancer field. In vitro modelling of cancer involving immune cells has a tremendous potential for elucidating new disease determinants and identifying new drug targets for cancer treatment.
This R&D program combine our expertise’s in biomarker imaging, cancer cell biology and immunology. By working in crossdisciplinary teams we develop 3D cancer cell models mimicking the real tumour microenvironment to the extent possible. Additionally, we develop techniques allowing e.g. infiltration of immune cells into such models.
During the program we will explore the use of artificial intelligence to develop prediction tools based on various biological data generated from the cancer cell models
Our ultimate goal is to expand our solutions in the cancer field by offering the best cancer cell models, especially within immune-oncology.
This R&D program combine our expertise’s in biomarker imaging, cancer cell biology and immunology. By working in crossdisciplinary teams we develop 3D cancer cell models mimicking the real tumour microenvironment to the extent possible. Additionally, we develop techniques allowing e.g. infiltration of immune cells into such models.
During the program we will explore the use of artificial intelligence to develop prediction tools based on various biological data generated from the cancer cell models
Our ultimate goal is to expand our solutions in the cancer field by offering the best cancer cell models, especially within immune-oncology.
Gene Editing & Immune models
Being able to modify the genome in human immune cells open up a wide range of possibilities to develop novel in vitro immune models for both Mode of Actions studies and safety across several diseases, including cancer.
Being able to modify the genome in human immune cells open up a wide range of possibilities to develop novel in vitro immune models for both Mode of Actions studies and safety across several diseases, including cancer.
The R&D program involve our experts in both gene editing and immunology, where our gene editing technologies are used to modify for T-cells, NK cells and macrophages.
In addition, protocols for differentiation of human induced pluripotent stem cells to a variety of immune cells will be developed, making it possible to perform gene editing on the stem cell stage followed by immune directed differentiation.
Our ambition is to develop novel human immune models providing the best solutions to companies across modalities including cell therapies, therapeutic antibodies and peptides.
Being able to modify the genome in human immune cells open up a wide range of possibilities to develop novel in vitro immune models for both Mode of Actions studies and safety across several diseases, including cancer.
The R&D program involve our experts in both gene editing and immunology, where our gene editing technologies are used to modify for T-cells, NK cells and macrophages.
In addition, protocols for differentiation of human induced pluripotent stem cells to a variety of immune cells will be developed, making it possible to perform gene editing on the stem cell stage followed by immune directed differentiation.
Our ambition is to develop novel human immune models providing the best solutions to companies across modalities including cell therapies, therapeutic antibodies and peptides.
Gastro-Intestinal Modelling
Bioneer has extensive experience in all aspects of in vitro gastro-intestinal modelling and the use of laboratory models to support drug formulation characterization and development.
We develop state-of-the-art laboratory models based on clinical data that take into account changes in the GI tract for selected diseases or conditions. This includes intestinal diseases and conditions leading to an elevated pH level in the stomach, which can be observed in different patient groups, especially among geriatric patients.
The Dynamic Gastric Model (DGM), which is normally used to simulate a healthy human gastric conditions, will be refined to also reflect selected disease conditions.
Our ambition with this program is to strengthen our gastro-intestinal in vitro models to mimic the human physiology in both healthy and diseased conditions.
Our affiliate in Copenhagen, Bioneer:FARMA, will develop state-of-the-art laboratory models based on clinical data that take into account changes in the GI tract for selected diseases or conditions. This includes intestinal diseases and conditions leading to an elevated pH level in the stomach, which can be observed in different patient groups, especially among geriatric patients.
The Dynamic Gastric Model (DGM), which is normally used to simulate a healthy human gastric conditions, will be refined to also relfect selected disease conditions.
Our ambition with this program is to strengthen our gastro-intestinal in vitro models to mimic the human physiology in both healthy and diseased conditions.
For further information
please contact:
